ArticleFrontiers in oncology2026
Interpretable machine learning integrating intra-/peritumoral CT radiomics and serum indicators for predicting poorly differentiated esophageal squamous cell carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To develop an interpretable ensemble learning model integrating multiple machine learning algorithms, intratumoral and peritumoral CT radiomics, and serum biomarkers for predicting poorly differentiated esophageal squamous cell carcinoma (ESCC). Methods: This retrospective study enrolled 261 ESCC patients, who were randomly allocated to training (n=183) and validation (n=78) cohorts. Radiomics features were extracted from intratumor, peritumoral 0.3 cm and intra-peritumoral 0.3 cm areas of enhanced CT arterial phase. Serum neutrophils (NEU) and alkaline phosphatase (ALP) were collected. Following feature dimensionality reduction, ensemble radiomics score (ENs) was calculated for each region. Seven individual machine learning models and an ensemble model (ENML) were subsequently constructed. Model performance was assessed using the area under the curve (AUC), confidence interval (CI) and decision curve analysis (DCA), while interpretability was evaluated via SHAP, correlation, and restricted cubic spline (RCS) analyses. Results: In the validation cohort, ENML achieved the highest AUC (0.799), F1 score (0.810), recall (0.870), and Brier score (0.166), and demonstrated clinical net benefit across threshold probabilities ranging from 10% to 75%. Bootstrap resampling with 1,000 iterations confirmed its stable performance in the full cohort (AUC: 0.849, 95% CI: 0.790-0.891). Spearman correlation analyses revealed strong positive associations between intratumoral and peritumoral radiomic features (r = 0.54, 0.49, and 0.51, respectively; all P < 0.001). RCS analyses identified significant nonlinear relationships between intratumor, intra-peritumoral 0.3 cm, ENs, and ALP levels and the increased incidence of poorly differentiated ESCC (Overall P < 0.05; Nonlinear P < 0.05). Additionally, both ALP and NEU exhibited significant inflection point effects in predicting poorly differentiated ESCC. SHAP analyses identified the IntraPeri3mm_wavelet.LLL_glszm_SmallAreaLowGrayLevelEmphasis and SVM as the primary contributors to the fusion model. Conclusions: The interpretable ENML model exhibits favorable discriminative capability for predicting poorly differentiated ESCC; however, further multicenter external validation is warranted to confirm its generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.